Prostatype Genomics announces strong results for Prostatype® in first step validation study of Asian population
Prostatype Genomics AB (”Prostatype Genomics” or ”The Company”) is releasing data from the first step of the previously communicated and ongoing validation study in Taiwan.In line with the Company’s overall strategy and communicated milestones, Prostatype Genomics is further expanding its clinical validation study programme and publishes data from the first step of the validation study in Taiwan in cooperation with Professor Jacob See-Tong Pang at the renowned Chang Gung Memorial Hospital in Linkou, Taoyuan. Fredrik Persson, Company CEO, comments: “We are excited to have completed